美国机器人胰腺切除术的应用与结局:工具变量分析
该研究基于2011至2023年Medicare索赔数据,纳入55,514例接受胰十二指肠切除术或远端胰腺切除术的受益人,采用工具变量分析比较开放、腹腔镜与机器人入路的90天结局。机器人胰腺切除术在研究期间快速增加,与开放手术相比严重并发症、再手术和90天死亡率更低,与腹腔镜结局相似,且在低容量医院各入路结局无差异。
要点
- 机器人胰十二指肠切除术和远端胰腺切除术分别增长12倍和3.6倍。
- 机器人较开放手术严重并发症、再手术和90天死亡率更低。
- 机器人入路在低容量医院未显示结局劣于其他入路。
核心结论
- 机器人辅助胰腺切除术在过去20年快速增长,促进了微创手术的渗透。
- 机器人辅助胰腺切除术与开放和腹腔镜手术相比结局不更差,包括在低容量机构。
- 这些发现支持对复杂胰腺手术采用机器人入路。
研究设计与样本
- 研究查询2011至2023年Medicare按服务收费受益人索赔数据,纳入接受远端胰腺切除术或胰十二指肠切除术的患者。
- 采用工具变量分析比较风险调整后的90天术后结局,工具变量为医院转诊区域上一年胰腺切除术机器人使用率。
- 医院按Leapfrog Group每年20例手术的截点进行容量分层。
- 共识别55,514例受益人:胰十二指肠切除术43,230例(机器人756例、腹腔镜753例、开放41,721例),远端胰腺切除术12,284例(机器人1,131例、腹腔镜981例、开放10,172例)。
主要发现
- 腹腔镜胰腺切除术在2014至2016年初次采用后增加,随后进入平台期。
- 机器人辅助胰十二指肠切除术和远端胰腺切除术在研究期间分别增长12倍和3.6倍,使微创胰腺切除术增加10个百分点。
- 与开放手术相比,机器人辅助胰腺切除术与显著更低的严重并发症发生率(10.4% vs 16.8%)、再手术率(5.7% vs 7.8%)和90天死亡率(5.2% vs 7.7%)相关。
- 机器人手术与腹腔镜手术的结局相似。
- 高容量中心结局总体更好,但在低容量医院内结局不因入路而异。
临床怎么用
- 在适合的胰腺切除术患者中,机器人入路可作为开放和腹腔镜手术的替代选择,不增加严重并发症、再手术或90天死亡风险。
- 在低容量医院,机器人胰腺切除术的结局与开放和腹腔镜相似,支持在非专科中心谨慎开展。
- 机器人胰腺切除术可能与更低的90天总 episode 支出相关,但需结合本地资源评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of minimally invasive surgery approaches has lagged in pancreatic surgery. Single-center studies support using robotic approaches for pancreatectomy, but as pancreatectomy expands outside specialty centers, current data may not reflect all practice settings. METHODS: We queried Medicare claims for fee-for-service beneficiaries undergoing distal pancreatectomy or pancreaticoduodenectomy from 2011 to 2023, capturing a varied population across practice settings. We used instrumental variable analysis to compare risk-adjusted 90-day postoperative outcomes between open, laparoscopic, and robotic approaches. The instrumental variable used was hospital referral region-level prior year pancreatectomy robotic use. Hospitals were volume stratified based on the Leapfrog Group's cutoff of 20 operations annually. RESULTS: We identified 55,514 beneficiaries: 43,230 pancreaticoduodenectomy (756 robotic, 753 laparoscopic, and 41,721 open) and 12,284 distal pancreatectomy (1,131 robotic, 981 laparoscopic, and 10,172 open). Laparoscopic pancreatectomy increased after initial adoption between 2014 and 2016 before plateauing. Robotic-assisted pancreaticoduodenectomy and distal pancreatectomy increased 12-fold and 3.6-fold over the study period, respectively, resulting in a 10-percentage point increase in minimally invasive surgery pancreatectomies. Robotic-assisted pancreatectomy was associated with significantly lower rates of serious complications (10.4% vs 16.8%), reoperation (5.7% vs 7.8%), and 90-day mortality (5.2% vs 7.7%) compared with open procedures. Outcomes were similar between robotic and laparoscopic procedures. While outcomes were overall better at high-volume centers, outcomes did not vary by approach within low-volume hospitals. Ninety-day total episode spending was lower for robotic as compared with open operations. CONCLUSION: There has been rapid growth in robotic-assisted pancreatectomy over the past 2 decades, resulting in improved penetration of minimally invasive surgery approaches. The use of robotic-assisted pancreatectomy is not associated with worse outcomes compared with open and laparoscopic procedures, including at low-volume institutions. These findings support the use of the robotic approach for this complex operation.
引用
- Savitch SL, Fleischer CM, Mullens CL, et al. Adoption and outcomes of robotic pancreatectomy in the United States: An instrumental variable analysis. Surgery. 2026. PMID: 42864158. doi:10.1016/j.surg.2026.110568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。